The PI3K/AKT/mTOR pathway has already represented an attractive target for developing targeted anti-cancer drugs for many years, and, indeed, many isoform-specific, pan-inhibitors, or dual PI3K/mTOR inhibitors have already entered the clinical evaluation and also undergone approval by regulatory agencies [1,2,3,4]. The gene discussed is PIK3CD; the disease is cancer.